A new drug added to standard treatment for advanced bladder cancer
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced or metastatic urothelial (bladder) cancer and are about to start or have recently started the standard treatment with enfortumab vedotin and pembrolizumab.
- You are generally able to care for yourself (ECOG score 0 or 1).
- Your cancer has not spread to the brain, or if it has, it has been stable for at least 4 weeks and is not causing symptoms needing more than 10 mg of prednisone daily.
- You do not have severe nerve damage (peripheral neuropathy) or poorly controlled diabetes.
- You have not had a severe allergic reaction to any monoclonal antibody (a type of biologic drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This Phase 1 study tests whether cabozantinib combined with enfortumab vedotin can help people with advanced urothelial (bladder) cancer that has already been treated with immunotherapy (PD-1/PD-L1) and usually chemotherapy. It aims to find a safer dose and see if the combo can shrink tumors or control the disease.
This study compares two drug combinations for advanced bladder cancer that has spread or cannot be removed with surgery. The drugs aim to help the immune system fight the cancer more effectively.
This trial tests a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for advanced bladder cancer that has not been treated with systemic therapy. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
Hear when a new Advanced Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.